Get the Stockscreener App
50.57
3.37%
1.65
Ptc Therapeutics Inc stock is traded at $50.57, with a volume of 1.05M.
It is up +3.37% in the last 24 hours and up +9.01% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$48.92
Open:
$49.42
24h Volume:
1.05M
Relative Volume:
0.92
Market Cap:
$4.02B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-8.5135
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+3.58%
1M Performance:
+9.01%
6M Performance:
-0.24%
1Y Performance:
+51.27%
1-Day Range:
$48.97
$51.00
1-Week Range:
$47.94
$54.24
52-Week Range:
$30.41
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
50.57 | 3.96B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst (NASDAQ:PTCT) - Seeking Alpha
Morgan Stanley lowers PT for PTC Therapeutics to $71 from $76. - AInvest
RBC says PTC Therapeutics CRL may signal difficulty for Biohaven - Yahoo Finance
PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital - Yahoo Finance
Charles Schwab Investment Management Inc. Cuts Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics' (NASDAQ:PTCT) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
FDA slaps CRL on PTC Therapeutics’ vatiquinone NDA - The Pharma Letter
PTC stung by FDA decision not to approve rare disease drug - pharmaphorum
PTC’s vatiquinone approval hopes dashed in Friedreich’s Ataxia - Yahoo Finance
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided - MSN
PTC Therapeutics, Inc. $PTCT Shares Sold by US Bancorp DE - MarketBeat
PTC Therapeutics, Inc. $PTCT Position Increased by Sector Gamma AS - MarketBeat
Nuveen LLC Acquires Shares of 1,009,168 PTC Therapeutics, Inc. $PTCT - MarketBeat
US FDA declines to approve PTC Therapeutics’ rare genetic disorder drug - WKZO
Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection - insights.citeline.com
PTC Therapeutics stock falls as FDA issues CRL for vatiquinone in FA - Investing.com Canada
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
PTC Therapeutics stock price target lowered to $63 at Jefferies on FDA rejection - Investing.com
PTC Therapeutics Surges on Q2 Earnings and Strategic Moves - StocksToTrade
US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder - Reuters
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns - inkl
100,000 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Public Sector Pension Investment Board - MarketBeat
US FDA declines to approve PTC Therapeutics' rare genetic disorder drug - Reuters
FDA rejects PTC’s Friedreich’s ataxia drug - Endpoints News
PTC Therapeutics Receives FDA Complete Response Letter - MSN
PTC Therapeutics rare disease therapy rejected (PTCT:NASDAQ) - Seeking Alpha
PTC Therapeutics stock falls after FDA rejects vatiquinone application - Investing.com
PTC Therapeutics Says FDA Issues CRL For Vatiquinone NDA In Friedreich's Ataxia - Nasdaq
Ptc Therapeutics receives complete response letter for Vatiquinone NDA - MarketScreener
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA | PTCT Stock News - GuruFocus
PTC Therapeutics and the FDA's August 19, 2025 PDUFA Deadline for Vatiquinone: Navigating Risk and Reward in Orphan Drug Development - AInvest
FDA Denies Approval: PTC Therapeutics' Vatiquinone for Rare Genetic Disease Friedreich's Ataxia Hits Setback - Stock Titan
PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds - Yahoo Finance
Is PTC Therapeutics Inc. stock a good dividend stockJuly 2025 Momentum & High Win Rate Trade Alerts - theviewers.co.kr
PTC Therapeutics, Inc. $PTCT Holdings Raised by Deutsche Bank AG - MarketBeat
PTC Therapeutics Gains FDA Approval for Sephience - MSN
Vanguard Group Inc. Has $438.63 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2025 Earnings Call Transcript - MSN
Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Price Target at $69.85 - MarketBeat
Leerink Partnrs Predicts Lower Earnings for PTC Therapeutics - MarketBeat
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
PTC Therapeutics’ SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com South Africa
Behind the Scenes of PTC Therapeutics's Latest Options Trends - Benzinga
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Lowered by Wall Street Zen - MarketBeat
PTC Therapeutics’ SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Ptc Therapeutics, Inc. shares rise 6.59% intraday after presenting at Oppenheimer 28th Annual Tech Conference. - AInvest
PTC Therapeutics: Stock Rises Amid Mixed Signals - TipRanks
Phenylketonuria Market to Witness Promising Upswing by 2034, - openPR.com
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
RBC Capital Initiates PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $63 - 富途牛牛
PTC Therapeutics’ Earnings Call Highlights Sephience Success - MSN
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ptc Therapeutics Inc Stock (PTCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO |
Aug 15 '25 |
Sale |
48.58 |
2,813 |
136,656 |
103,901 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):